Rezolute completes enrollment in Phase 3 tumor hyperinsulinism study

October 14, 2026 4:05 PM

Rezolute, Inc. (NASDAQ: RZLT) announced the completion of enrollment in its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found